---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Care management intervention strategies"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Care management intervention strategies. Topics: Post-procedural monitoring after Kebilidi administration: label and FDA review, Pre-procedure imaging in Aetna criteria for Kebilidi: stereotactic planning MRI, Long-term follow-up after AAV gene therapy: FDA guidance, EHDN multidisciplinary position paper: managed care network and case manager, and 7 further topics. 12 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Summary

- Procedure and monitoring analogs: the prescribing information for Kebilidi, a product administered by stereotactic neurosurgery, directs monitoring for procedure-related adverse events, including continuous cardiorespiratory monitoring during hospitalization, and the FDA review states that procedural complications can be mitigated by post-procedural monitoring. Aetna considers brain MRI for stereotactic planning and intraoperative navigation medically necessary for members being considered for Kebilidi.
- Long-term follow-up: FDA guidance recommends long-term follow-up of up to five years for AAV vectors, with a risk-based approach to duration for vectors capable of long term expression without integration, such as AAV.
- Multidisciplinary care: a multidisciplinary position paper recommends a multidisciplinary team, an individualised care and treatment plan for every patient and family, and a case manager or coordinator. The Huntington's Disease Society of America states that no one doctor or caregiver should manage all aspects of an HD case, and that the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life. HDSA Centers of Excellence provide neurologists, psychiatrists, social workers, therapists, counselors, and other professionals.
- Advance care planning: one guideline describes advance care planning as essential, including discussion of alternative feeding methods, and another recommends documenting living wills and care directives early and social worker support for financial assistance. In one study, engaging in advance care planning did not cause untoward effects on health-related quality of life or suicidal thoughts and behavior (STB), whose lifetime prevalence in HD approaches 30%.
- Palliative care: a review included 38 of 333 articles and found a low level of evidence for most topics. One publication states that referral to palliative care should be strongly considered for patients with pain, anxiety, sleep disturbances, and difficulty coping with the diagnosis.

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download); [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download); [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html); [FDA long term follow-up after gene therapy guidance (2020)](https://www.fda.gov/media/113768/download); [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/); [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf); [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/); [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full); [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/); [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/); [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/); [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)

<a id="topic-2.2.2.4-2"></a>

### Post-procedural monitoring after Kebilidi administration: label and FDA review

> “Monitor patients for procedure related adverse events with KEBILIDI administration, including”
> “continuous cardiorespiratory monitoring during hospitalization.”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

> “The major risks of KEBILIDI include procedural-related complications and dyskinesia and can be mitigated by post-procedural monitoring and use of dopamine antagonists, respectively.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.2.2.4-3"></a>

### Pre-procedure imaging in Aetna criteria for Kebilidi: stereotactic planning MRI

> “Brain MRI will be used for stereotactic planning and intraoperative navigation; and”
> “Aetna considers the following tests and procedures medically necessary for members being considered for treatment with Kebilidi:”
> “Brain magnetic resonance imaging (MRI) for stereotactic planning and intraoperative navigation.”

Source: [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.4-4"></a>

### Long-term follow-up after AAV gene therapy: FDA guidance

> “In general, our current recommendations for the duration of a LTFU protocol based on product type are as follows:”
> “Up to five years for AAV vectors.”
> “Additionally, a risk-based approach for determining the duration of a LTFU protocol may be considered for vectors capable of latency (e.g., Herpesvirus), long term expression without integration (e.g., AAV), or vectors carrying gene editing components.”

Source: [FDA long term follow-up after gene therapy guidance (2020)](https://www.fda.gov/media/113768/download)

<a id="topic-2.2.2.4-5"></a>

### EHDN multidisciplinary position paper: managed care network and case manager

> “The multidisciplinary team should be composed of different professionals who work closely together and interact within the group. It is also important to establish an individualised care and treatment plan for every single case of a patient and family. A case manager or coordinator may facilitate the work of the multidisciplinary team.”
> “This position paper reveals that there are key essential professional groups involved in the MDT who do not have an HD guideline available, like psychologists, social workers, nurses, case managers and general practitioners.”

Source: [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/)

<a id="topic-2.2.2.4-6"></a>

### HDSA physician's guide: team care and Centers of Excellence

> “No one doctor or one caregiver should attempt to manage all aspects of an HD case without assistance.”
> “Because there are no treatments which can slow, halt, or reverse the course of the disease, the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

<a id="topic-2.2.2.4-7"></a>

### HDSA Centers of Excellence: team composition

> “Patients benefit from expert neurologists, psychiatrists, social workers, therapists, counselors and other professionals who have extensive experience working with families affected by HD and who work collaboratively to help families plan the best HD care program throughout the course of the disease.”

Source: [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)

<a id="topic-2.2.2.4-8"></a>

### Advance care planning: EHDN guideline

> “Advanced care planning is essential and alternative feeding methods (PEG, see swallowing disorders) should be anticipated and discussed with relatives and patients still able to understand the benefits and risks of the intervention.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.4-9"></a>

### Advance care planning and psychosocial support: German Neurological Society guideline

> “Early in the disease process, it is recommended to document living wills and care directives”
> “Moreover, there should be support from a social worker to navigate the complex bureaucracy to apply for and obtain financial assistance and support for care needs.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.4-10"></a>

### Advance care planning: multicenter HDQLIFE study

> “Most importantly, engaging in ACP does not cause untoward effects on HRQoL or STB for this rare neurodegenerative disease where the lifetime prevalence of STB approaches 30%.”

Source: [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/)

<a id="topic-2.2.2.4-11"></a>

### Palliative care in advanced disease: scoping review

> “Our search resulted in 333 articles, 38 of which were included.”
> “Most literature was underpinned by a low level of evidence, except for the topics on social care (Level III-V), advance care planning (Level II-V) and end-of-life needs assessments (Level II-III).”

Source: [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/)

<a id="topic-2.2.2.4-12"></a>

### Palliative care across disease stages

> “But for those with pain, anxiety, sleep disturbances, and difficulty coping with their diagnosis, referral to palliative care should be strongly considered.”

Source: [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)

Additional sources: [El-Sourady et al. (2022)](https://journals.sagepub.com/doi/full/10.1089/jpm.2021.0308); [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36698999/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
